Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?

On Thursday, the FDA granted full approval to Humacyte, Inc.’s HUMA Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible.Symvess, or the ATEV, is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for arterial replacement and repair.Also Read: Delay Hits Humacyte’s Bioengineered Hum ...